Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
enGene Holdings Inc. Warrants (ENGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ENGNW (1-star) is a SELL. SELL since 2 days. Profits (-28.57%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -26.5% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 |
52 Weeks Range 0.42 - 2.74 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.35% | Return on Equity (TTM) -33.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 26066719 |
Shares Outstanding - | Shares Floating 26066719 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
enGene Holdings Inc. Warrants
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing gene therapies for localized diseases. The warrants represent the right to purchase shares of the company's common stock. The history of the warrants is tied to the company's financial transactions, such as IPO or SPAC merger. Specifics on the enGene warrants history are not widely available outside of official filings.
Core Business Areas
- Gene Therapy Development: Focused on developing gene therapies for localized diseases, leveraging its non-viral delivery platform, DDX platform.
- Platform Technology: Developing the DDX platform for targeted delivery of genetic payloads.
Leadership and Structure
The leadership team consists of executives specializing in gene therapy, clinical development, and finance. The organizational structure typically involves departments focused on research, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- EG-70: Lead product candidate; Phase 2 trial ongoing for high-risk Bacillus Calmette-Guu00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Data is not yet available in terms of revenue or market share. Competitors include companies developing alternative bladder cancer treatments, such as CG Oncology with cretostimogene grenadenorepvec and ImmunityBio with N-803.
Market Dynamics
Industry Overview
The gene therapy market is experiencing significant growth driven by technological advancements and increasing regulatory approvals. This includes oncology treatments and therapies for other localized diseases.
Positioning
enGene is positioned as a developer of targeted gene therapies, utilizing its unique non-viral delivery system. It competes with other gene therapy companies and traditional pharmaceutical companies in its target indications.
Total Addressable Market (TAM)
The TAM for gene therapies targeting specific localized diseases such as NMIBC is significant, potentially reaching billions of dollars. enGene is positioned to capture a portion of this market with its DDX platform and lead candidate EG-70.
Upturn SWOT Analysis
Strengths
- Proprietary DDX delivery platform
- Targeted gene therapy approach
- Phase 2 clinical trial for EG-70
Weaknesses
- Limited product pipeline beyond EG-70
- Reliance on clinical trial success
- Dependence on funding for ongoing research and development
- Warrants can cause dilution to common shares
Opportunities
- Expanding the application of DDX platform to other diseases
- Partnering with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Competition from established gene therapy companies
- Regulatory hurdles
- Changes in the reimbursement landscape
Competitors and Market Share
Key Competitors
- CG Oncology (CGON)
- ImmunityBio (IBRX)
- Replimune Group Inc. (REPL)
Competitive Landscape
The market is competitive with both emerging and established gene therapy companies, as well as traditional pharmaceutical companies. enGene's DDX platform offers a potential competitive advantage. *Note: These numbers reflect current actual revenue market share. Companies such as ENGN are pre-revenue so their share is listed at 0%.
Growth Trajectory and Initiatives
Historical Growth: enGene's historical growth is tied to progress in its research and development programs.
Future Projections: Future growth depends on clinical trial successes and potential commercialization of EG-70 or other pipeline candidates.
Recent Initiatives: Recent initiatives include advancement of EG-70 clinical trials and exploration of new applications for the DDX platform.
Summary
enGene Holdings Inc. is a clinical-stage biotech company with a promising gene therapy delivery platform and a lead candidate in Phase 2 trials. The company's success hinges on positive clinical trial outcomes and securing adequate funding. Key challenges include competition from larger biotech companies and the inherent risks associated with drug development. The warrants provide investors with the option to participate in the potential upside, but also expose them to the downside risks of the underlying company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market data may not be real-time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Warrants
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.